RCKT
Rocket Pharmaceuticals Inc

3,113
Mkt Cap
$370.12M
Volume
239,242.00
52W High
$15.00
52W Low
$2.19
PE Ratio
-1.52
RCKT Fundamentals
Price
$3.34
Prev Close
$3.42
Open
$3.47
50D MA
$3.41
Beta
1.19
Avg. Volume
2.1M
EPS (Annual)
-$2.73
P/B
1.18
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Bank of America Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price
Bank of America lowered their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday...
MarketBeat·16d ago
News Placeholder
More News
News Placeholder
JPMorgan Chase & Co. Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Underweight
JPMorgan Chase & Co. lowered Rocket Pharmaceuticals from a "neutral" rating to an "underweight" rating in a research report on Tuesday...
MarketBeat·16d ago
News Placeholder
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Hold" from Brokerages
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have earned a consensus rating of "Hold" from the eighteen research firms that are covering the stock, MarketBeat reports. Three...
MarketBeat·16d ago
News Placeholder
Quinn Opportunity Partners LLC Takes Position in Rocket Pharmaceuticals, Inc. $RCKT
Quinn Opportunity Partners LLC bought a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·21d ago
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Outperform Rating from Wedbush
Wedbush reaffirmed an "outperform" rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday...
MarketBeat·26d ago
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results, Beats Expectations By $0.03 EPS
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping...
MarketBeat·27d ago
News Placeholder
Rocket Pharmaceuticals, Inc. Q3 Loss Decreases, Beats Estimates
(RTTNews) - Rocket Pharmaceuticals, Inc. (RCKT) revealed Loss for third quarter that decreased from last year and beat the Street estimates...
Nasdaq News: Markets·29d ago
News Placeholder
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Business Wire·29d ago
News Placeholder
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Zacks·2mo ago
News Placeholder
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Business Wire·2mo ago

Latest RCKT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.